Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (1316)	12/2/1997 1:01:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4676

James: Yes. Cell article have positive spin, regardless the negative results, and your points are important in drug development. Regards the antisense as TI Nebraska patent cover nucleotide sequence complementary to repeat telemeter unit in telomerase RNA. Geron patents (one on small molecules inhibitor and other on antisense) cover sequence at 5'- RNA region, while Isis antisense, IMO, will be against 3'-RNA region (RNase H mechanism). Which one will work best depend on antisense potency and side effects. No way to predict anything. Initially I was thinking that development of the small molecules TI will be relatively quickly, translation and experience from HIV RT. It appears that story is not that simple. Will see. mz